Substituted benzothiophene analogs as selective estrogen receptor degraders

Patent metadata

Field	Value
Publication number	US-12295939-B2
Application number	US-202318364621-A
Country	US
Kind code	B2
Filing date	Aug 3, 2023
Priority date	Feb 6, 2018
Publication date	May 13, 2025
Grant date	May 13, 2025

Abstract

In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of treating one or more clinical conditions associated with estrogen receptor, such as a cancer, including breast cancer, or osteoporosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

First claim

What is claimed is:

1. A method for the treatment of breast cancer in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a compound having a structure represented by a formula:

wherein m is selected from 0 and 1;
wherein p is selected from 0, 1, and 2;
wherein q is selected from 0, 1, and 2;
wherein each of Z 1 and Z 2 is independently selected from —CH— or —N—; provided Z 1 and Z 2 are not simultaneously —CH— or —N—; and provided when Z 1 is —CH— and m is 1, that p and q are not both 0;
wherein Z 10 is selected from —O— or —NH;
wherein Z 11 is, when present, —CH 2 CH 2 ;
wherein Z 40 is —(CH 2 ) n —, wherein n is selected from 1, 2, 3, or 4;
wherein each of R 10a and R 10b are independently selected from hydrogen, deuterium, halogen, and C1-C3 methyl;
wherein R is C1-C6 alkyl, C1-C6 haloalkyl, halogen, or hydroxy; and
r is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the breast cancer is selected from the group consisting of hormone receptor positive metastatic breast cancer, tamoxifen resistant breast cancer, aromatase inhibitor resistant breast cancer, CDK4/6 inhibitor resistant breast cancer breast cancer, a triple negative breast cancer, and combinations thereof.

3. The method of claim 2 , further comprising co-administering a hormone therapy agent.

4. The method of claim 3 , wherein the hormone therapy agent is selected an antibody that specifically binds bicalutamide, flutamide, fulvestrant, leuprolide acetate, megestrol acetate, tamoxifen, raloxifene, anastrozole, exemestane, letrozole, and combinations thereof.

5. The method of claim 2 , further comprising co-administering a therapeutic antibody selected from the group consisting of an antibody that binds EGFR, an antibody that binds PD-1, an antibody that binds PD-L1, an antibody that binds VEGF, an antibody that binds HER2, and combinations of the foregoing antibodies thereof.

6. The method of claim 5 , wherein the therapeutic antibody is selected from the group consisting of panitumumab, bevacizumab, cetuximab, trastuzumab, and combinations thereof.

7. The method of claim 2 , further comprising co-administering a therapeutic agent selected from the group consisting of a chemotherapeutic agent, a radioisotope, an anti-hormonal agent, a cytotoxic agent, an immunotherapeutic agent, a targeted cancer therapeutic agent, and combinations thereof.

8. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of folate antagonists, purine antagonists, pyrimidine antagonists, DNA alkylating agents, DNA cross-linking drugs, antibiotics, platinum complexes, and combinations thereof.

9. The method of claim 7 , wherein the targeted cancer therapeutic agent is selected from the group consisting of proteosome inhibitors, mitotic spindle poisons, topoisomerase inhibitors, tyrosine kinase inhibitors, CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, BET (Bromodomain and Extra-Terminal motif proteins) inhibitors, and combinations thereof.

10. The method of claim 1 , wherein Z 10 is —O—.

11. The method of claim 1 wherein —Z 1 — is N and Z 2 is —CH—.

12. The method of claim 1 wherein —Z 1 — is —CH— and Z 2 is —N—.

13. The method of claim 1 , having a structure represented by a formula:

or a subgroup thereof.

14. The method of claim 1 , having a structure represented by a formula:

15. The method of claim 1 , having a structure represented by a formula:

Assignees

• Univ Illinois

Inventors

• Thatcher Gregory R
• Xiong Rui
• Zhao Jiong
• Lu Yunlong
• Gutgesell Lauren
• Rosales Carlo Ivan
• Li Yangfeng

Classifications

• C07D409/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K38/09

  Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides · CPC title